Table 2 Treatment-emergent adverse events occurring in ≥30% of patients treated with MK-2206 plus trastuzumab ( n = 31)
Adverse event | All grades (%) | Grade 3 (%) | Grade 4 (%) |
|---|---|---|---|
Fatigue | 71.0 | 0 | 0 |
Hyperglycemia | 51.8 | 6.5 | 0 |
Rash | 58.1 | 16.7 | 0 |
Nausea | 48.4 | 0 | 0 |
Alkaline phosphatase increase | 45.2 | 6.5 | 0 |
Aspartate aminotransferase increase | 45.2 | 9.7 | 0 |
Decreased appetite | 41.9 | 0 | 0 |
Diarrhea | 35.5 | 0 | 0 |
Alanine aminotransferase increase | 32.3 | 3.2 | 3.2 |
Decreased hemoglobin | 32.3 | 3.2 | 0 |
Dyspepsia | 32.3 | 0 | 0 |
Hypoalbuminenia | 32.3 | 0 | 0 |
Vomiting | 32.3 | 0 | 0 |